• Presented at International Association of Parkinsonism and Related Disorders (IAPRD) 2020

  • Collaborator: Ipsen

  • Authors: J. Ferreira, C. Comella, M. Azoulai, E. Pain, S. Om

Botulinum neurotoxin type A (BoNT-A) is an effective pharmacological treatment for the management of cervical dystonia (CD) that requires repeated administration at variable intervals.

Objective: Understand the patient perspective on the impacts of botulinum neurotoxin-A (BoNT-A) ‘wearing-off’ (waning of therapeutic effect) on daily function and quality of life (QoL).